Medicines
Our data-driven, science-first drug development mindset inspires us to pursue meaningful treatments to help patients.
Striving to give more hope to patients
Our success in advancing clinical programs and establishing a commercial product franchise has been fueled by our team’s fervent belief in the science behind our molecules.
Exelixis programs
Partnered programs
MINNEBRO® (esaxerenone)
Marketed by Daiichi Sankyo and available in Japan, only
U.S. Medical Support
Adverse event reporting
If you want to report an adverse event related to use of CABOMETYX® (cabozantinib) or COMETRIQ® (cabozantinib), please email drugsafety@exelixis.com or call 1-855-500-3935 (EXEL).
Product quality complaints
If you want to report a product quality complaint related to use of CABOMETYX or COMETRIQ, please call 1-855-500-3935 (EXEL).
Medical information questions
If you are a healthcare professional and have a question about an Exelixis product, please contact Exelixis Medical Information at medinfo@exelixis.com or call 1-855-292-3935 (EXEL).
This page is intended for U.S. residents only
Ipsen has an exclusive license to commercialize cabozantinib outside of the United States and Japan. Please visit www.ipsen.com for more information.
Takeda has an exclusive license to commercialize cabozantinib in Japan. Please visit www.takeda.com for more information.